Viewing Study NCT06027268


Ignite Creation Date: 2025-12-24 @ 5:39 PM
Ignite Modification Date: 2025-12-29 @ 1:34 PM
Study NCT ID: NCT06027268
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-17
First Post: 2023-08-31
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Sponsor: Wake Forest University Health Sciences
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module